Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care

We aimed to evaluate the accuracy of the Panbio™ Ag-RDT at primary health care (PHC) centers and test sites in symptomatic patients and close contacts, using the Reverse-Transcription Polymerase Chain Reaction (RT-PCR) test as the gold standard. The study was conducted in four PHC centers and two te...

Descripción completa

Detalles Bibliográficos
Autores: Bulilete, Oana, Lorente-Montalvo, Patricia, Leiva, Alfonso, Carandell Jäger, Eugenia, Oliver, Antonio, Rojo Molinero, Estrella, Pericàs Pulido, Pau, Llobera Cànaves, Joan
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/18179
Acceso en línea:https://hdl.handle.net/20.500.13003/18179
Access Level:acceso abierto
Palabra clave:Male
SARS-CoV-2
Spain
Adult
Female
Humans
COVID-19
Sensitivity and Specificity
Primary Health Care
Middle Aged
Humanos
Persona de Mediana Edad
Femenino
Atención Primaria de Salud
Adulto
España
Masculino
Sensibilidad y Especificidad
Rapid antigen test
Sar-CoV-2
id ES_6cebc6d90c3a5da35f2fbffb2bd1b27d
oai_identifier_str oai:docusalut.com:20.500.13003/18179
network_acronym_str ES
network_name_str España
repository_id_str
spelling Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health careBulilete, OanaLorente-Montalvo, PatriciaLeiva, AlfonsoCarandell Jäger, EugeniaOliver, AntonioRojo Molinero, EstrellaPericàs Pulido, PauLlobera Cànaves, JoanMaleSARS-CoV-2SpainAdultFemaleHumansCOVID-19Sensitivity and SpecificityPrimary Health CareMiddle AgedSensitivity and SpecificitySARS-CoV-2HumanosPersona de Mediana EdadFemeninoAtención Primaria de SaludCOVID-19AdultoEspañaMasculinoSensibilidad y EspecificidadCOVID-19Rapid antigen testPrimary Health CareSar-CoV-2We aimed to evaluate the accuracy of the Panbio™ Ag-RDT at primary health care (PHC) centers and test sites in symptomatic patients and close contacts, using the Reverse-Transcription Polymerase Chain Reaction (RT-PCR) test as the gold standard. The study was conducted in four PHC centers and two test sites in Mallorca, Spain. Consecutive patients older than 18 years, attending the sites for RT-PCR testing were included. Two nasopharyngeal samples were collected, one for RT-PCR and the other was processed on-site using the Panbio™ rapid antigen test kit for SARS-CoV-2. The sensitivity and specificity were calculated using RT-PCR as the reference, and the predictive values using the pretest probability results for each analyzed group. A total of 1369 participants were included; mean age 42.5 ± 14.9 years and 54.3% women. The overall prevalence was 10.2%. Most participants (70.6%) presented within 5 days of the onset of symptoms. The overall sensitivity was of 71.4% (95% CI: 63.1%, 78.7%), the specificity of 99.8% (95% CI: 99.4%, 99.9%), the positive predictive value of 98.0% (95% CI: 93.0%, 99.7%) and a negative predictive value of 96.8% (95% CI: 95.7%, 97.7%). The sensitivity was higher in symptomatic patients, in those arriving within 5 days since symptom onset and in those with high viral load. Ag-RDT had relatively good performance characteristics in suspected symptomatic patients within five days since the onset of symptoms. However, our data do not support the sole use of Panbio™ Ag-RDT in asymptomatic individuals. None.Elsevier20212021-02-1320212021-02-13research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/18179reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/181792026-06-22T12:44:07Z
dc.title.none.fl_str_mv Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care
title Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care
spellingShingle Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care
Bulilete, Oana
Male
SARS-CoV-2
Spain
Adult
Female
Humans
COVID-19
Sensitivity and Specificity
Primary Health Care
Middle Aged
Sensitivity and Specificity
SARS-CoV-2
Humanos
Persona de Mediana Edad
Femenino
Atención Primaria de Salud
COVID-19
Adulto
España
Masculino
Sensibilidad y Especificidad
COVID-19
Rapid antigen test
Primary Health Care
Sar-CoV-2
title_short Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care
title_full Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care
title_fullStr Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care
title_full_unstemmed Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care
title_sort Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care
dc.creator.none.fl_str_mv Bulilete, Oana
Lorente-Montalvo, Patricia
Leiva, Alfonso
Carandell Jäger, Eugenia
Oliver, Antonio
Rojo Molinero, Estrella
Pericàs Pulido, Pau
Llobera Cànaves, Joan
author Bulilete, Oana
author_facet Bulilete, Oana
Lorente-Montalvo, Patricia
Leiva, Alfonso
Carandell Jäger, Eugenia
Oliver, Antonio
Rojo Molinero, Estrella
Pericàs Pulido, Pau
Llobera Cànaves, Joan
author_role author
author2 Lorente-Montalvo, Patricia
Leiva, Alfonso
Carandell Jäger, Eugenia
Oliver, Antonio
Rojo Molinero, Estrella
Pericàs Pulido, Pau
Llobera Cànaves, Joan
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Male
SARS-CoV-2
Spain
Adult
Female
Humans
COVID-19
Sensitivity and Specificity
Primary Health Care
Middle Aged
Sensitivity and Specificity
SARS-CoV-2
Humanos
Persona de Mediana Edad
Femenino
Atención Primaria de Salud
COVID-19
Adulto
España
Masculino
Sensibilidad y Especificidad
COVID-19
Rapid antigen test
Primary Health Care
Sar-CoV-2
topic Male
SARS-CoV-2
Spain
Adult
Female
Humans
COVID-19
Sensitivity and Specificity
Primary Health Care
Middle Aged
Sensitivity and Specificity
SARS-CoV-2
Humanos
Persona de Mediana Edad
Femenino
Atención Primaria de Salud
COVID-19
Adulto
España
Masculino
Sensibilidad y Especificidad
COVID-19
Rapid antigen test
Primary Health Care
Sar-CoV-2
description We aimed to evaluate the accuracy of the Panbio™ Ag-RDT at primary health care (PHC) centers and test sites in symptomatic patients and close contacts, using the Reverse-Transcription Polymerase Chain Reaction (RT-PCR) test as the gold standard. The study was conducted in four PHC centers and two test sites in Mallorca, Spain. Consecutive patients older than 18 years, attending the sites for RT-PCR testing were included. Two nasopharyngeal samples were collected, one for RT-PCR and the other was processed on-site using the Panbio™ rapid antigen test kit for SARS-CoV-2. The sensitivity and specificity were calculated using RT-PCR as the reference, and the predictive values using the pretest probability results for each analyzed group. A total of 1369 participants were included; mean age 42.5 ± 14.9 years and 54.3% women. The overall prevalence was 10.2%. Most participants (70.6%) presented within 5 days of the onset of symptoms. The overall sensitivity was of 71.4% (95% CI: 63.1%, 78.7%), the specificity of 99.8% (95% CI: 99.4%, 99.9%), the positive predictive value of 98.0% (95% CI: 93.0%, 99.7%) and a negative predictive value of 96.8% (95% CI: 95.7%, 97.7%). The sensitivity was higher in symptomatic patients, in those arriving within 5 days since symptom onset and in those with high viral load. Ag-RDT had relatively good performance characteristics in suspected symptomatic patients within five days since the onset of symptoms. However, our data do not support the sole use of Panbio™ Ag-RDT in asymptomatic individuals. None.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-02-13
2021
2021-02-13
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/18179
url https://hdl.handle.net/20.500.13003/18179
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410303067815936
score 15.811543

Similares en LA Referencia